The rapid uptake of YUTREPIA and transition to profitability suggest strong commercial viability. Traders should monitor prescription growth, litigation developments with United Therapeutics, and progress on L606 pivotal trials as key catalysts. The ability to fund growth from operations reduces near-term dilution risk.
Price Chart
Executive Summary
Liquidia Technologies reported strong full-year 2025 financial results driven by $148.3 million in net product sales of YUTREPIA®, its inhaled treprostinil therapy for PAH and PH-ILD, launched in June 2025. The company achieved its second consecutive profitable quarter with $14.6 million in net income in Q4 and ended the year with $190.7 million in cash, up from $176.5 million in Q3. Despite a reduced net loss of $68.9 million for the full year (down from $128.3 million in 2024), the commercial momentum and self-funded growth plans signal strong market adoption.
Key Financial Metrics
Key Facts
- YUTREPIA® generated $148.3 million in net product sales in 2025, with $90.1 million in Q4 alone
- Company achieved second consecutive profitable quarter with $14.6 million net income in Q4 2025
- Cash and cash equivalents increased to $190.7 million as of December 31, 2025, up $33.2 million from Q3
- Net loss for 2025 was $68.9 million, a significant improvement from $128.3 million in 2024
- More than 3,600 unique prescriptions and 2,900 patients treated since launch in June 2025
- Selling, general and administrative expenses rose 93% to $157.2 million, primarily due to YUTREPIA commercialization
Financial Impact
YUTREPIA generated $148.3 million in revenue in its first full year post-launch, representing a new core revenue stream. The drug drove profitability in the second half of 2025, with positive non-GAAP EBITDA of $27.3 million in Q4.
Risk Factors
- Ongoing patent litigation with United Therapeutics could result in an injunction blocking YUTREPIA sales
- High SG&A spend ($157.2M) raises questions about long-term margin sustainability
- Service revenue declined $4.0 million due to lower Treprostinil Injection sales, indicating potential erosion in legacy business
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3249963 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 12d ago | 8-K | $33.94 $34.78 | ▲ +2.48% | ▲ +2.19% | $43.74 (+28.87%) |
Oct 13, 2026 12d ago | Insider Cluster | $33.94 $34.78 | ▲ +2.48% | ▲ +2.19% | $43.74 (+28.87%) |
Sep 30, 2026 26d ago | 8-K | $27.99 $28.64 | ▼ −2.32% | ▼ −1.58% | $43.74 (−56.27%) |
Sep 3, 2026 7w ago | 8-K | $68.63 $68.66 | ▲ +0.04% | ▲ +0.43% | $43.74 (−36.27%) |
Sep 3, 2026 7w ago | Press Release | $68.63 $68.66 | ▲ +0.04% | ▲ +0.43% | $43.74 (−36.27%) |
Aug 25, 2026 8w ago | Insider Cluster | $71.36 $69.94 | ▼ −1.99% | ▼ −2.65% | $43.74 (−38.71%) |
Aug 21, 2026 9w ago | Insider Cluster | $70.27 $70.49 | ▲ +0.31% | ▼ −0.01% | $43.74 (−37.75%) |
Aug 12, 2026 10w ago | 8-K | $78.79 $72.10 | ▼ −8.49% | ▼ −9.19% | $43.74 (−44.49%) |
Aug 12, 2026 10w ago | Press Release | $78.79 $72.10 | ▲ +8.49% | ▲ +9.19% | $43.74 (+44.49%) |
Jul 29, 2026 12w ago | Insider Cluster | $86.80 $84.11 | ▼ −3.10% | ▼ −3.82% | $43.74 (−49.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers